Effect of <i>N</i>‐acetyl cysteine in children with metabolic dysfunction‐associated steatotic liver disease—A pilot study

Abstract

Sixteen-week NAC treatment was well tolerated in children with obesity and MASLD and led to improvements in oxidative stress, inflammation and IR and liver outcomes. The results from this pilot study support further investigation of NAC as a therapeutic agent in children with MASLD.